In addition, we also compared the action of CS055 to another pan-HDAC inhibitor SAHA (also known as vorinostat, approved by FDA for treatment of cutaneous T-cell lymphoma). This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.